GSK and SCYNEXIS Announce an Exclusive Agreement to Commerci

Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with... | March 30, 2023

Related Keywords

Jersey , Washington , United States , Middlesex , United Kingdom General , United Kingdom , New York , London , City Of , Philadelphia , Pennsylvania , Brentford , Hounslow , China , Jeff Mclaughlin , Luke Miels , James Dodwell , David Angulo , Dan Smith , Tim Foley , Camilla Campbell , Lyndsay Meyer , Irina Koffler , Nick Stone , Josh Williams , Vulvovaginal Candidiasis , Mick Readey , Debbie Etchison , Kathleen Quinn , Steph Mountifield , Spero Therapeutics Inc , Nasdaq , Exchange Commission , Globenewswire Inc , Drug Administration , Scynexis Inc , Chief Commercial Officer , Chief Executive Officer , Investor Relations , Intensive Care Unit , Spero Therapeutics , Sci Advisors , Annual Report , Private Securities Litigation Reform Act , Quarterly Report , Gsk Plc Stock Exchange , News , Information , Press Release , Rexafemme , Complements , Nfectious , Disease , Portfolio , Ith , N , Fda , Approved , Treatment , Or , Ulvovaginal , Andidiasisscynexis , Hill , Eceive , Upfront , Payment , F , Illion Gsk Gb00bn7swp63 ,